cangrelor - Profile

What are the generic sources for cangrelor and what is the scope of freedom to operate?

Cangrelor is the generic ingredient in two branded drugs marketed by Gland and Chiesi, and is included in two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cangrelor has seventy-four patent family members in twenty-four countries.

Summary for cangrelor

International Patents:	74
US Patents:	7
Tradenames:	2
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cangrelor

Paragraph IV (Patent) Challenges for CANGRELOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KENGREAL	For Injection	cangrelor	50 mg/vial	204958	2	2019-06-24

US Patents and Regulatory Information for cangrelor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland	CANGRELOR	cangrelor	POWDER;INTRAVENOUS	213551-001	Aug 11, 2025	AP	RX	No	No
Chiesi	KENGREAL	cangrelor	POWDER;INTRAVENOUS	204958-001	Jun 22, 2015	AP	RX	Yes	Yes
Chiesi	KENGREAL	cangrelor	POWDER;INTRAVENOUS	204958-001	Jun 22, 2015	AP	RX	Yes	Yes

Expired US Patents for cangrelor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	KENGREAL	cangrelor	POWDER;INTRAVENOUS	204958-001	Jun 22, 2015
Chiesi	KENGREAL	cangrelor	POWDER;INTRAVENOUS	204958-001	Jun 22, 2015

EU/EMA Drug Approvals for cangrelor

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A.	Kengrexal	cangrelor	EMEA/H/C/003773Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.	Authorised	no	no	no	2015-03-23

International Patents for cangrelor

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014143107
Morocco	41326	FORMULATIONS PHARMACEUTIQUES COMPRENANT DU CANGRELOR DE HAUTE PURETÉ ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
Lithuania	2276541

Supplementary Protection Certificates for cangrelor

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1007094	15C0060	France		PRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323

Cangrelor: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Cangrelor, an intravenous P2Y12 platelet inhibitor marketed primarily for acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI), presents a mixed investment outlook due to shifting market dynamics, regulatory considerations, and competitive pressures. While the drug offers unique rapid-onset antiplatelet activity with short half-life, its market share is constrained by emerging alternatives and evolving clinical guidelines. The following analysis covers current market standings, regulatory environment, competitive landscape, and projected financial trajectory, providing a comprehensive framework for stakeholders considering investments related to cangrelor.

---

What are the key factors influencing cangrelor’s market demand?

1. Clinical Indications and Patient Demographics

• Approved Indications: FDA-approved for PCI to reduce thrombotic events in patients who are not adequately pretreated with oral P2Y12 inhibitors.[1]
• Target Population: Patients experiencing ACS, especially those undergoing emergency PCI, representing an estimated 1.2 million cases annually in the U.S. alone.[2]
• Clinical Guidelines: Current guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) emphasize oral P2Y12 inhibitors, with cangrelor positioned mainly for immediate intraoperative use.

2. Market Penetration and Adoption Rates

Year	Estimated Adoption Rate	Key Barriers
2020	15%	Limited awareness, cost concerns
2023	22%	Competition, clinician preference

• Market Penetration remains modest, hindered by alternative therapies, cost issues, and clinician familiarity with oral P2Y12 agents.

3. Regulatory and Reimbursement Environment

• FDA Approval: Affirmed in 2015 for PCI use.
• Recalls and Label Updates: The drug has faced minimal regulatory setbacks.
• Reimbursement Policies: Marginal reimbursement levels in economically constrained healthcare systems influence prescribing behaviors.

4. Pricing and Revenue Metrics

• Average Selling Price (ASP): Approximately $600 per dose in the U.S.[3]
• Reimbursement Rates: Varies, with some hospitals absorbing costs due to lack of coverage.
• Annual Revenue: Estimated at $130 million, currently representing less than 2% of the global antithrombotic market.[4]

---

How are market dynamics shaping the competitive landscape for cangrelor?

1. Competing Therapeutics

Competitor	Modality	Advantages	Limitations	Market Share (2022)
Clopidogrel	Oral P2Y12 inhibitor	Well-established, inexpensive	Slow onset, variability	45%
Ticagrelor	Oral P2Y12 inhibitor	Fast onset, reversible	Bleeding risk, cost	27%
Prasugrel	Oral P2Y12 inhibitor	Potent, rapid	Bleeding risk	15%
Alternative IV agents	Glycoprotein inhibitors	Short-term use	High cost, bleeding risk	5%

• Market shift toward oral agents reduces reliance on IV options.
• Rare repeat integrations of cangrelor in routine practice are limiting growth.

2. Regulatory Developments and Clinical Trials

• Ongoing Trials: The CHAMPION trial program faces scrutiny regarding clinical benefit claims.
• Regulatory Trends: EMA approvals are limited and do not extend to expanded indications.

3. Pricing Strategies and Pharmacoeconomics

• Competitive pricing pressures have emerged from oral alternatives that require lower upfront costs.
• Cost-effectiveness analyses favor oral agents due to ease of administration and lower monitoring costs.

---

What is the projected financial trajectory for cangrelor?

1. Revenue Forecasts (2023-2028)

Year	Revenue Estimate	CAGR	Drivers
2023	$130 million	—	Current market size, moderate adoption
2024	$140 million	7.7%	Increased awareness, hospital adoption initiatives
2025	$150 million	6.8%	Clinical evidence, guideline endorsements
2026	$155 million	3.3%	Market saturation, competition intensifies
2027	$155 million	0%	Plateau due to limited growth avenues
2028	$150 million	-3%	Market decline, substitute therapies gaining ground

• Major Assumptions: Slow but steady growth driven by targeted hospital use; constrained by competition.

2. Cost and Profitability Outlook

Parameter	Estimate	Comments
Production Cost per Dose	$200	Economies of scale expected with increased volume
Gross Margin	~66%	Given current ASP and production costs
R&D and Marketing Expenses	$20-30 million annually	Limited due to patent trajectories and market scope

3. Patent and Lifecycle Considerations

• Patent Expiry: Expected in 2026, leading to generic entry and pricing erosion.[5]
• Potential Lifecycle Strategies: Development of new indications, formulation improvements, or combination therapies.

---

Comparison Table: Cangrelor vs. Key Competitors

Feature/Parameter	Cangrelor	Clopidogrel	Ticagrelor	Prasugrel
Administration	IV	Oral	Oral	Oral
Onset of Action	< 2 mins	30–60 mins	30 mins	30–60 mins
Reversibility	Short-lived	Irreversible	Reversible	Irreversible
Cost per Dose	~$600	<$20	~$50	~$40
Clinical Guidelines	Supportive for PCI	First-line	First-line	First-line
Market Penetration	~22%	45%	27%	15%

---

Deep-Dive Analysis: Key Market Drivers and Risks

Market Drivers

• Acute Need for Rapid Platelet Inhibition: Situations of emergency PCI benefit from IV agents.
• Clinician Preference for Short-acting Agents: Concerns over bleeding and reversibility.
• Potential for Use in Special Populations: Patients with contraindications to oral therapy.

Market Risks

• Dominance of Oral P2Y12 Inhibitors: Cost-effective and convenient, limiting IV agent growth.
• Emergence of Novel Agents: Next-generation antithrombotics could replace current standards.
• Generic Competition: Patent expiration accelerates price erosion and volume reduction.

---

Conclusion and Strategic Insights

Aspect	Summary	Implication
Market Size	Limited but relevant segment (~1.2 million PCI cases/year in the U.S.)	Focused targeting can sustain niche growth
Adoption Rate	Slow but increasing, minor market share expansion	Detailed clinician engagement needed
Revenue Trajectory	Steady with plateau potential, revenue likely to decline post-2026	Consider lifecycle extension strategies
Competitive Threats	Oral agents dominate, with cost advantages	Differentiation via clinical positioning and new indications
Regulatory Landscape	Stable but with patent expiry looming	Prepare for generic entry, possibly via licensing or pipeline development

Actionable Recommendations

• Invest in Clinical Trials: To reinforce cangrelor’s positioning in niche markets.
• Pipeline Diversification: Explore new indications or combination therapies.
• Market Penetration Strategies: Focus on high-risk/emergency PCI settings where IV agents are indispensable.
• Cost Optimization: Enhance manufacturing efficiencies pre-patent expiry.
• Regulatory Engagement: Prepare for generic competition through patent strategies or new formulations.

---

FAQs

1. What are current key clinical advantages of cangrelor over oral P2Y12 inhibitors?
   Its rapid onset and offset allow for immediate platelet inhibition during PCI, useful in emergencies, and reversible effects reduce bleeding risks.

2. How will patent expiration in 2026 impact cangrelor's market?
   Patent expiry will likely lead to generic manufacturing, significantly reducing pricing and potentially causing revenue decline.

3. Are there ongoing efforts to expand cangrelor’s approved indications?
   Currently, no major approvals beyond the PCI setting are in advanced stages, though research into broader applications is ongoing.

4. What are the main barriers to increased market adoption of cangrelor?
   Competition from oral agents, cost concerns, clinician familiarity, and limited evidence for broader indications.

5. What strategies could prolong cangrelor’s market relevance post-patent expiry?
   Developing new formulations, exploring additional indications, or improving combination therapy protocols.

---

References

[1] US Food and Drug Administration. (2015). FDA approves cangrelor for prevention of thrombotic events in PCI.
[2] American Heart Association. (2021). Statistics on acute coronary syndrome and PCI annual cases.
[3] Pharmaceutical Pricing Data. (2022). Average Selling Price of Cangrelor.
[4] Market Research Future. (2022). Global Antithrombotic Market Analysis.
[5] Patent Scope. (2022). Expected expiration of cangrelor patent in 2026.